| Phase 13 trials |
|
Phase 1
|
NCT07411586 |
Aug 2026 → Jan 2027 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07130695 |
Feb 2026 → Oct 2028 expected |
acute myeloid leukemia |
Virginia Commonwealth University |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06543381 |
Jan 2025 → Feb 2027 expected |
acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
City of Hope Medical Center |
Recruiting
|
No outcome recorded
|
| Phase 1/24 trials |
|
Phase 1/2
|
NCT06445959 |
Aug 2024 → Jun 2027 expected |
— |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04013880 |
Aug 2019 → Mar 2021 |
acute myeloid leukemia, myelodysplastic syndrome |
Vanderbilt-Ingram Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT03684811 |
Nov 2018 → May 2021 |
chondrosarcoma, intrahepatic cholangiocarcinoma, malignant glioma |
Forma Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02719574 |
Apr 2016 → Dec 2023 |
acute myeloid leukemia, myelodysplastic syndrome |
Forma Therapeutics, Inc. |
Completed
|
No outcome recorded
|
| Phase 211 trials |
|
Phase 2
|
NCT07471841 |
Jul 2026 → Jun 2028 expected |
acute myeloid leukemia |
Timothy Pardee |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07604064 |
Jun 2026 → Sep 2030 expected |
acute myeloid leukemia |
Kissei Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07153497 |
May 2026 → Apr 2030 expected |
acute myeloid leukemia, myelodysplastic syndrome |
National Cancer Institute (NCI) |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06782542 |
Mar 2026 → Mar 2029 expected |
acute myeloid leukemia |
Justin Watts, MD |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07304011 |
Dec 2025 → Dec 2027 expected |
acute myeloid leukemia |
University of California, Davis |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07032727 |
Sep 2025 → Jun 2027 expected |
— |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06161974 |
Feb 2025 → Jun 2029 expected |
astrocytoma, IDH-mutant, grade 4, diffuse midline glioma, H3 K27M-mutant, grade III glioma, metastatic malignant neoplasm in the brain +3 |
Rigel Pharmaceuticals |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06597734 |
Jan 2025 → Jun 2026 |
chronic myelomonocytic leukemia, myelodysplastic syndrome |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06668584 |
Dec 2024 → Dec 2027 expected |
myeloid neoplasm |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06566742 |
Dec 2024 → Aug 2027 expected |
chronic myelomonocytic leukemia, clonal hematopoiesis of indeterminate potential, myelodysplastic syndrome |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05564390 |
Jun 2024 → May 2029 expected |
acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
| Phase 41 trial |
|
Phase 4
|
NCT07486713 |
Feb 2026 → Apr 2027 expected |
acute myeloid leukemia, cholangiocarcinoma, glioma |
Rigel Pharmaceuticals |
Recruiting
|
No outcome recorded
|